A clinical assessment of mycophenolate drug monitoring after liver transplantation

Clinical Transplantation

Volumn 24, Issue 2, 2010, Pages

  Hwang, Shin ^a   Lee, Sung Gyu ^a   Ahn, Chul Soo ^a   Kim, Ki Hun ^a   Moon, Deok Bog ^a   Ha, Tae Yong ^a   Song, Gi Won ^a   Jung, Dong Hwan ^a   Choi, Nam Kyu ^a   Kim, Kwan Woo ^a   Yu, Young Dong ^a   Park, Gil Chun ^a   Park, Pyoung Jae ^a   Choi, Young Il ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Immunosuppression; Liver transplantation; Mycophenolate mofetil; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; TACROLIMUS;

EID: 77952940912     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01166.x     Document Type: Article

References (27)

1. Jain A, Vekatramanan R, Eghtesad B. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005, 80:859.
2. Jain A, Kashyap R, Dodson F. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001, 72:1091.
3. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 2005, 139:2.
4. Sintchak MD, Fleming MA, Futer O. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996, 85:921.
5. Brunet M, Cirera I, Martorell J. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006, 81:541.
6. Tredger JM, Brown NW, Adams J. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004, 10:492.
7. Jain A, Venkataramanan R, Hamad IS. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001, 41:268.
8. Bilbao I, Castells L, Rojas L. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006, 6:1977.
9. Orlando G, Baiocchi L, Cardillo A. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007, 13:46.
10. Schmeding M, Neumann UP, Neuhaus R. Mycophenolate mofetil in liver transplantation - is monotherapy safe? Clin Transplant 2006, 20(Suppl. 17):75.
11. Hwang S, Lee SG, Lee YJ. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006, 12:920.
12. Moon DB, Lee SG. Adult-to-adult living donor liver transplantation at the Asan Medical Center. Yonsei Med J 2004, 45:1162.
13. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006, 82:579.
14. Vivarelli M, Cucchetti A, Piscaglia F. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005, 11:497.
15. Vivarelli M, Bellusci R, Cucchetti A. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002, 74:1746.
16. Berenguer M. Management of hepatitis C virus in the transplant patient. Clin Liver Dis 2007, 11:355.
17. Figueras J, Prieto M, Bernardos A. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 2006, 19:641.
18. Shaw LM, Nawrocki A, Korecka M. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit 2004, 26:347.
19. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005, 80:S244.
20. Van Gelder T, Klupp J, Barten M. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001, 23:119.
21. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Drugs 1998, 34:429.
22. Aw MM, Brown NW, Itsuka T. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003, 9:383.
23. Brown NW, Aw MM, Mieli-Vergani G. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002, 24:598.
24. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004, 10:1189.
25. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34:429.
26. Pisupati J, Jain A, Burckart G. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005, 45:34.
27. Hesselink DA, Van Hest RM, Mathot RA. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005, 5:987.